Back to companies

Curevac NV: Overview

Select Item

Related keylists

Curevac NV (Curevac) is a clinical-stage biopharmaceutical company that develops RNA-based medicines. The company develops, designs, and produces messenger RNA molecules for therapeutic and prophylactic vaccines in the fields of oncology and infectious diseases. Its product pipeline includes Cv0501, Cv2cov, Flu Sv Mrna and Cvsqiv. Curevac mRNA-based prophylactic vaccine candidates comprise cv7202 and cv8102. it also carries out research and development. The company Cv8102, a lead oncology candidate is designed to modulate the tumor microenvironment. Its products are used in the treatment of prostate cancer and non-small cell lung cancer and infectious diseases such as rabies, rotavirus and influenza. CureVac is headquartered in Tubingen, Baden-Wurttemberg, Germany.

 Gain a 360-degree view of Curevac NV and make more informed decisions for your business Gain a 360-degree view of Curevac NV and make more informed decisions for your business Contact Us
Headquarters Germany
Address Friedrich-Miescher-Str. 15, Tuebingen, Baden-Wurttemberg, 72076
Website www.curevac.com
Telephone 49 7071 98830
No of Employees 1,049
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange CVAC (NASD)
Revenue (2022) $70.9M -34.5% (2022 vs 2021)
EPS XYZ
Net Income (2022) XYZ 39.5% (2022 vs 2021)
Market Cap* $1.2B
Net Profit Margin (2022) XYZ 7.6% (2022 vs 2021)
* As of and is in US$
View Curevac NV financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Contact Us

Curevac NV premium industry data and analytics

70+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Curevac NV’s relevant decision makers and contact details.

50+

Pipeline Drugs

Identify which of Curevac NV’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

40+

Catalyst Calendar

Proactively evaluate Curevac NV’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

30+

Clinical Trials

Determine Curevac NV go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

6

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

5

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Curevac NV’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products
CV0501 (COVID-19 Vaccine Candidate)
CV2CoV (COVID-19 Vaccine Candidate)
CVSQIV
XYZ
XYZ
XYZ
Understand Curevac NV portfolio and identify potential areas for collaboration Understand Curevac NV portfolio and identify potential areas for collaboration Contact Us

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Litigation In July, the company filed a patent infringement lawsuit against BioNTech in Germany over intellectual property rights of messenger ribonucleic acid (mRNA) technology.
2022 Acquisitions/Mergers/Takeovers In June, the company acquired Frame Cancer Therapeutics (Frame Therapeutics), a pharmaceutical company.
2022 Contracts/Agreements In May, the company announced to enter into a partnership with myNEO to identify specific cancer antigens in order to develop novel mRNA immunotherapies for cancer vaccines.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Contact Us
Image for loader

Competitor Comparison

Key Parameters Curevac NV Pfizer Inc AstraZeneca Plc Moderna Inc BioNTech SE
Headquarters Germany United States of America United Kingdom United States of America Germany
City Tuebingen New York Cambridge Cambridge Mainz
State/Province Baden-Wurttemberg New York England Massachusetts Nordrhein-Westfalen
No. of Employees 1,049 83,000 83,500 3,900 4,530
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Contact Us
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Contact Us
Executives
Name Position Board Since Age
Alexander Zehnder Chief Executive Officer Senior Management 2023 -
Pierre Kemula Chief Financial Officer Senior Management 2016 49
Malte Greune Chief Operating Officer Senior Management 2021 58
Antony Blanc Chief Business Officer and Chief Commercial Officer Senior Management 2020 55
Myriam Mendila Chief Development Officer Senior Management 2023 -
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Non Dignissim Eros Proin vel Convallis 2023 XY
Gain insight into Curevac NV key executives to enhance your sales strategy Gain insight into Curevac NV key executives to enhance your sales strategy Contact Us
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward